Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing www.jci.org May 16, 2024, 9:35 p.m.
Chimeric antigen receptor (CAR) designs that incorporate pharmacologic control are desirable; however, designs suitable for clinical translation are needed. We designed a fully human, rapamycin-regulated drug product for targeting CD33+ tumors called dimerizaing agent–regulated immunoreceptor complex (DARIC33). T cell products demonstrated target-specific and rapamycin-dependent cytokine release, transcriptional responses, cytotoxicity, and in vivo antileukemic activity in the presence of as little as 1 nM rapamycin. Rapamycin withdrawal paused DARIC33-stimulated T cell effector functions, which were restored following reexposure to rapamycin, demonstrating reversible effector function control.
Preliminary Findings Point to Low Risk of Secondary Cancers from CAR-T Therapies www.biospace.com May 10, 2024, 2:38 p.m.
At a joint event held by the Friends of Cancer Research and Parker Institute for Cancer Immunotherapy on Monday, cell therapy pioneer Carl June of the University of Pennsylvania Perelman School of Medicine revealed findings from a recent unpublished study from his group that looked at 783 patients who had received CAR-T treatments for HIV-1 or various cancers. Over more than 2,200 patient-years of observation, the group found 18 patients, or 2.3%, who developed secondary malignancies.
Strengthening CAR-T therapy to work against solid tumors medicalxpress.com May 10, 2024, 2:37 p.m.
The promising findings, reported in Science Advances, involve CAR-T cell therapy, which supercharges the immune system to identify and attack cancer cells. The paper is titled "TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors."
Review Describes Semaglutide-Associated Skin Effects www.medscape.com May 4, 2024, 1:13 p.m.
Alopecia, dysesthesia, and other types of skin sensations have been reported in patients treated with semaglutide, but more research is needed to understand skin findings associated with this drug.
La chronicisation des maladies : un nouveau paradigme social www.lequotidiendupharmacien.fr April 30, 2024, 7:02 p.m.
La chronicisation des maladies représente un défi pour la médecine du XXIe siècle. L’augmentation du nombre de patients atteints d’une affection chronique rend incontournable une réflexion sur l’enjeu social et économique que constitue leur prise en charge.
CARMAT www.carmatsa.com April 29, 2024, 4:21 a.m.
Carmat ambitionne de répondre à un enjeu majeur de santé publique lié aux maladies cardiovasculaires, l’insuffisance cardiaque, qui représente la première cause de décès dans le monde. Plus précisément, Carmat vise à apporter une solution durable au traitement de l’insuffisance cardiaque terminale, maladie pour laquelle il existe aujourd’hui très peu d’options efficaces, la principale étant la transplantation cardiaque.
Avancée majeure : les tumeurs ne seraient pas forcément induites par des mutations génétiques www.futura-sciences.com April 26, 2024, 2:17 a.m.
Si des études ont déjà souligné l'influence de l'épigénétique dans le développement de tumeurs, c'est la première fois qu'il est démontré que les mutations de l’ADN - qui s'accumulent au niveau du génome - ne sont pas indispensables à l'apparition des cancers. En d'autres termes, cette découverte montre que des processus pas forcément génétiques sont entièrement capables de provoquer l'apparition et le développement de tumeur, ouvrant ainsi la voie à de nouvelles pistes thérapeutiques.
How Are Hypodermic Needles Made? www.mpo-mag.com April 21, 2024, 2:22 p.m.
Today’s hypodermic needles are hollow devices made from flat sheets of stainless steel heated to achieve pliability. Fabrication then occurs by rolling stainless steel strips into a tubular shape and using a laser to weld the two seams.
Résistance aux antibiotiques : un constat alarmant www.leprogres.fr April 16, 2024, 9:01 a.m.
Le Groupe de direction mondial sur la résistance aux antimicrobiens – antibiotiques notamment – appelle les Etats membres de l’ONU à réagir urgemment face à cette menace croissante. Sa dernière étude laisse envisager un coût humain et économique vertigineux si des mesures fortes ne sont pas rapidement prises contre la résistance aux antimicrobiens.
Subcutaneous Immunotherapy: Better Life for Cancer Patients www.medscape.com April 14, 2024, 10:58 a.m.
Instead of waiting anywhere from 30 minutes to several hours for infusions into their veins, patients would spend just a few minutes being injected under the loose skin of their abdomens or thighs. Clinicians would save time and money, and patients would leave the clinic much sooner than normal. The ease of subcutaneous injections also opens up an opportunity for home treatment, a potential boon for people who don't want to spend their remaining time on hospital visits.
CAR T Cell Therapies Last Longer, Work Better with FOXO1 Protein www.genengnews.com April 14, 2024, 8:10 a.m.
Fewer than 50% of patients who are treated with CAR T therapies remain cured after one year. One of the reasons for this is that CAR T cells often don’t survive long enough in patients to completely eradicate their cancer. However, other studies showed that patients who were cured by CAR T therapy had cells that were more durable and able to fight the cancer longer. Results from the Nature study indicate that longer lasting cells benefit from a protein called FOXO1, which improves the survival and function of CAR T cells.
Researchers stimulate gene that enhances CAR T-cell treatments for solid tumors medicalxpress.com April 14, 2024, 8:09 a.m.
CAR T-cell therapy is a type of cancer treatment that genetically modifies your own immune T-cells to recognize and fight cancer. This treatment has been successful in some blood cancers but is less effective in solid cancers for several reasons, including poor cell persistence and functionality in a hostile tumor environment. The latest research, using ovarian, breast and colon cancer models, has identified a gene that can be stimulated to make the cells younger, fitter, more dynamic and effective in fighting solid tumors.
Poseida examines CAR-T conditioning to crack into solid tumors www.fiercebiotech.com April 14, 2024, 8:06 a.m.
Why haven’t CAR-T therapies cracked into solid tumors yet? Poseida Therapeutics is trying to fill in at least one piece of the puzzle with a new analysis presented at the American Association for Cancer Research annual meeting showing that patients may need a higher dose of lymphodepletion than those with blood cancers.
FDA approves earlier use of Carvykti CAR-T for multiple myeloma www.healio.com April 14, 2024, 8:02 a.m.
The expanded indication permits treatment with the chimeric antigen receptor T cells after first relapse and applies to adults who are refractory to lenalidomide and have received at least one previous line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Compounding Pharmacies for Semaglutide Cause Concern www.medscape.com April 13, 2024, 11:24 a.m.
In June, the FDA released a warning about the new antiobesity medications, stating it had received reports of adverse events after people self-administered semaglutide from a compounding pharmacy. The warning also states that compounding pharmacies may be selling salt forms of the active ingredient, including semaglutide sodium and semaglutide acetate, though the FDA is not aware of any basis for compounding a drug using semaglutide salts that would meet federal requirements.
Concerns Rising Over Risk that Ozempic May Cause Birth Control to Fail www.aboutlawsuits.com April 9, 2024, 12:32 p.m.
Health experts urge women not to use Ozempic or similar drugs to increase fertility, due to increased risks of birth defects and miscarriage.
A Novel Noninvasive Method for Treating Alzheimer’s Disease www.azonano.com April 1, 2024, 1:06 p.m.
A paradigm change in the understanding of Alzheimer’s pathogenesis has been made evident by recent research, highlighting the significance of concentrating on the soluble oligomeric form of the pathogenic amyloid beta (A-beta) protein to target its early-stage aggregation.
How can medical device OEMs support the circular economy? www.medtechdive.com April 1, 2024, 10:23 a.m.
“First, do no harm” is as central to the circular economic mindset as it is to the ethos of caregivers. This philosophy is making its way into boardrooms via environmental, social and governance (ESG) policies and it’s prompting medical device manufacturers to rethink their approach to design, production and what happens after the sale.
Tendances clés en 2024 dans le secteur de la santé www.capgemini.com April 1, 2024, 10:13 a.m.
Bien que la COVID ait perdu son statut d’urgence, le secteur de la santé publique continue de traiter avec “des cicatrices profondes sur notre monde“. La crise a souligné d’énormes lacunes dans nos systèmes de santé, en particulier dans la capacité des responsables de la santé publique à coordonner une réponse informée et rapide. Il y a un nouvel élan pour la digitalisation rapide des systèmes de santé. Il y a une reconnaissance de l’importance de placer les personnes au-dessus des processus. Et il y a une urgence croissante à fournir des services de santé durables. Par-dessus tout, les dirigeants reconnaissent maintenant que chacun de ces objectifs dépend d’une stratégie de données, avec un accès sécurisé et simple aux données de santé.
Why Physicians Resist Using Algorithm-Based Apps hbr.org April 1, 2024, 10:09 a.m.
A limited study of physicians in the United Kingdom’s National Health Service found that they are resistant to using algorithm-based tools, including AI-based applications. The research, which consisted of interviews with 32 physicians, identified four reasons for their reluctance. This article suggests ways their resistance can be overcome.